Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates.
暂无分享，去创建一个
J. Salomon | P. de Truchis | A. Dinh | B. Davido | O. Sénard
[1] M. Bonilla,et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[2] M. Rottman,et al. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa , 2017, Antimicrobial Agents and Chemotherapy.
[3] R. Bonomo,et al. In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model , 2017, Antimicrobial Agents and Chemotherapy.
[4] R. Humphries,et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? , 2017, Antimicrobial Agents and Chemotherapy.
[5] G. Damanhouri,et al. New Delhi Metallo-β-Lactamase (NDM-1): An Updates , 2011, Journal of chemotherapy.